In line, proteasome inhibition by Bortezomib (Velcade) is known to have combinatory effects with PI3K inhibition by BEZ treatment in mantel cell lymphomas 60 and diffuse large B-cell lymphoma in vitro61. This evidence concerns the gene PIK3CA and diffuse large B-cell lymphoma.